



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 13.11.2020

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor
Plot No.62, G- Block, Opp Trident Hotel,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 098

Dear Sir,

Sub: outcome of the Board Meeting held today i.e., on 13th November, 2020 -- Reg.

We wish to inform you that the Board of Directors at its Meeting held today i.e., 13th November, 2020 has inter-alia, transacted the following items of business:.

1. Approved the Un-Audited financial Results, along with the Cash Flow Statement, for the quarter and half year ended 30th September, 2020, as recommended by the audit committee and reviewed by the Statutory Auditors of the Company.
2. Approved the Statement of Assets and Liabilities as at 30th September, 2020.
3. Took note of the Limited Review Report on Un-Audited Financial statements for the quarter and half year ended 30th September, 2020.

This is for your information and necessary records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited




(Boina Kumar)

Chief Financial Officer

Meeting Commenced at 4:00 P.M.
Meeting Concluded at 4:30 P.M.

SIGACHI LABORATORIES LIMITED

Regd.Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273,

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN:L24230TG1994PLC018786

Statement of Un-Audited Financial Results for the Quarter and Half year Ended 30th September, 2020

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Revenue from operations	70.90	84.61	29.98	155.51	56.96	66.51
2	Other income	11.86	1.54	17.51	13.40	67.81	106.07
3	Total Income (1+2)	82.76	86.15	47.49	168.91	124.77	172.58
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Change in Inventories	-	-	-	-	-	-
	d) Employee benefits expense	7.24	5.30	5.79	12.54	15.19	27.99
	e) Finance costs	-	-	-	-	-	-
	f) Depreciation and amortization expense	4.14	4.14	3.56	8.28	7.13	15.32
	g) Other expenses	2.15	2.68	3.39	4.83	6.96	12.64
	Total Expenses	13.53	12.12	12.74	25.65	29.28	55.96
5	Profit/(loss) before exceptional and extraordinary items and tax (3-4)	69.23	74.03	34.75	143.26	95.49	116.62
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before extraordinary items and tax (5-6)	69.23	74.03	34.75	143.26	95.49	116.62
8	Extraordinary items	-	-	-	-	-	-
9	Profit/(Loss) before tax (7-8)	69.23	74.03	34.75	143.26	95.49	116.62
10	Tax expense						
	(a) Current tax	10.66	5.75	6.75	16.41	12.00	44.03
	(b) Deferred tax	(1.85)	0.20	0.14	(1.65)	0.28	1.94
	Total Tax Expense	8.81	5.95	6.89	14.76	12.28	45.97
11	Profit/(Loss) for the Period (9-10)	60.42	68.08	27.86	128.50	83.21	70.65
12	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or loss	55.07	158.32	(12.05)	213.39	(25.98)	(226.96)
	(b) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	55.07	158.32	(12.05)	213.39	(25.98)	(226.96)
	Total Comprehensive income (11+12)	115.49	226.40	15.81	341.89	57.23	(156.31)
13	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
14	Other Equity	-	-	-	-	-	1,256.34
15	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.))						
	(1) Basic	0.89	1.01	0.41	1.90	1.23	1.05
	(2) Diluted	0.89	1.01	0.41	1.90	1.23	1.05

T
RAJASEKH
AR
 Digitally signed
 by T RAJASEKHAR
 Date: 2020.11.13
 16:31:30 +05'30'

Segment wise Revenue, Results and Capital Employed for the Quarter & Half year ended 30th September, 2020

(Rs.in Lakhs)

Sl.No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	28.50	19.00	27.00	47.50	45.00	110.50
	b) Investments	54.26	67.15	20.49	121.41	79.77	62.08
	Total	82.76	86.15	47.49	168.91	124.77	172.58
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	82.76	86.15	47.49	168.91	124.77	172.58
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	24.20	14.33	23.51	38.53	36.94	93.55
	b) Investments	54.26	67.15	20.49	121.41	79.77	62.07
	Total	78.46	81.48	44.00	159.94	116.71	155.62
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	9.23	7.45	9.25	16.68	21.22	39.00
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	69.23	74.03	34.75	143.26	95.49	116.62
3	Capital Employed						
	(Segment assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	601.43	578.89	493.85	601.43	493.85	576.05
	b) Investments	1,727.85	1,634.90	1,702.92	1,727.85	1,702.92	1,411.34
	Total	2,329.28	2,213.79	2,196.77	2,329.28	2,196.77	1,987.39

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 13th November, 2020.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The outbreak of COVID-19 continues to spread across the globe and India, which has contributed to a significant decline and volatility in global and Indian Financial Markets and a significant decrease in the economic activities. On 11th March, 2020, the COVID-19 outbreak was declared as a global pandemic by the World Health Organisation. On 24th March, 2020, the Indian Government had announced a strict 21 day lockdown which kept on getting extended across the country with gradual and modest relaxations. Given the dynamic nature of the pandemic situation, the carrying value of the Company's investments and loans as at September 30, 2020, may be affected by the severity and duration of the outbreak.; however the Company believes that it has taken into account all the possible impact of known events arising out of COVID 19 pandemic in the preparation of financial results resulting out of fair valuation of these investments. However the impact assessment of COVID 19 is a continuing process given its nature and duration. The Company will continue to monitor for any material changes to future economic conditions.
- Previous year/period figures have been recasted/regrouped/reclassified wherever necessary to make them comparable with current year/period figures.

By Order of the Board
for SIGACHI LABORATORIES LIMITED

T
RAJASEKHAR
Digitally signed
by T RAJASEKHAR
Date: 2020.11.13
16:32:30 +05'30'

(T.R.Sekhar)
Executive Director
DIN:02943146

Place: Hyderabad
Date :13.11.2020

SIGACHI LABORATORIES LIMITED
CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2020

(Rs. In Lakhs)

Particulars	Half Year Ended		Year Ended
	30.09.2020	30.09.2019	31.03.2020
Cash Flows from Operating Activities			
Net profit before tax	143.26	95.49	116.62
Adjustments for :			
Depreciation and amortization expense	8.28	7.13	15.32
Profit/Loss on Sale of Investments	-	-	-
Dividend Received	(7.17)	(11.97)	(26.95)
Provision for Gratuity & Leave Encashment	-	-	0.95
Profit on Margadarshi Chit	-	(3.34)	(3.34)
Bad Deposits Recovery	-	(0.12)	(0.61)
Profit on sale of assets (Land)	-	(50.72)	(63.16)
Interest Received	(43.44)	(22.46)	(65.72)
Fair Value (Gains)/Losses	(77.97)	12.16	97.70
Operating profit before working capital changes	22.96	26.16	70.81
Movements in Working Capital			
(Increase)/Decrease in Trade Receivables	1.12	9.72	(6.17)
(Increase)/Decrease in Other financial assets	(0.48)	(2.91)	(107.29)
(Increase)/Decrease in Inventories	-	-	-
(Increase)/Decrease in Other Current Assets	(31.55)	(4.81)	(76.05)
(Increase)/Decrease in Other Non Current Assets	-	18.31	26.12
Increase/(Decrease) in Trade Payables	-	-	-
Increase/(Decrease) in Other financial liabilities	(5.76)	(46.68)	(38.96)
Increase/(Decrease) in Other Current liabilities	-	-	-
Increase/(Decrease) in Other Non Current Liabilities	-	-	-
Changes in Working Capital	(36.67)	(26.37)	(202.35)
Cash generated from operations	(13.71)	(0.20)	(131.55)
Direct Taxes Paid	(12.67)	0.50	35.17
Net Cash from operating activities (A)	(26.38)	(0.71)	(166.72)
Cash flows from Investing Activities			
Purchase of Fixed Assets	-	-	(21.53)
Sale of Fixed Assets	-	11.68	16.05
(Purchase)/Sale of Investments (Net Aggregate)	(32.09)	(46.71)	(123.49)
Dividend Received	7.17	11.97	26.95
Profit on Margadarshi Chit	-	3.34	3.34
Bad Deposits Recovery	-	0.12	0.61
Profit on sale of assets (Land)	-	50.72	63.16
Interest Received	43.44	22.46	65.72
(Increase)/Decrease in other term deposits	(8.77)	(42.63)	143.20
Net Cash used in Investing Activities (B)	9.75	10.96	174.01
Cash flows from/(used in) Financing Activities			
Proceeds from Long term borrowings	-	-	-
Repayment/(Proceeds) of/from Short-term borrowings	-	-	-
Dividend paid	-	-	-
Corporate Dividend tax	-	-	-
Net Cash used in Financing Activities (C)	-	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(16.63)	10.25	7.29
Cash and Cash Equivalents at the beginning of the year	210.17	202.88	202.88
Cash and Cash Equivalents at the ending of the year	193.54	213.13	210.17

By Order of the Board
for SIGACHI LABORATORIES LIMITED

T
RAJASEKHAR
Digitally signed by
T RAJASEKHAR
Date: 2020.11.13
16:32:52 +05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad
Date : 13.11.2020

SIGACHI LABORATORIES LIMITED Regd.Office: S.No: 530 & 534, Bonthapally - 502 313. Gummadidala Mandal, Sanga Reddy District, Telangana. Tel No.: 040 - 23204230 / 23204273, Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in CIN:L24230TG1994PLC018786 Statement of Assets and Liabilities as at 30th September, 2020. (Rs. In Lakhs)		
Particulars	As at 30.09.2020	As at 31.03.2020
A. ASSETS		
1. Non-Current Assets		
(a) Property Plant and Equipment	253.36	261.65
(b) Financial Assets		
(i) Investments	1,555.08	1,239.05
(ii) Other Financial Assets	43.53	43.53
(c) Other non Current Assets	-	-
Total Non - Current Assets	1,851.97	1,544.23
2. Current Assets		
(a) Financial Assets		
(i) Investments	37.45	21.26
(ii) Trade Receivables	19.73	20.85
(iii) Cash and Cash Equivalents	193.54	210.17
(iv) Other Financial Assets	172.77	172.29
(b) Other Current Assets	107.60	76.05
Total Current Assets	531.09	500.62
Total Assets	2,383.06	2,044.85
B. EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	731.06	731.06
(b) Other Equity	1,598.22	1,256.34
Total Equity	2,329.28	1,987.40
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(b) Long term Provisions	1.96	1.96
(c) Deferred Tax Liabilities (net)	17.66	19.31
(d) Other non - Current Liabilities	25.00	25.00
Total Non - Current Liabilities	44.62	46.27
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	-	-
(iii) Other Financial Liabilities	5.42	11.18
(b) Provisions	3.74	-
(c) Other Current Liabilities	-	-
Total Current Liabilities	9.16	11.18
Total Equity and Liabilities	2,383.06	2,044.85

By Order of the Board
for SIGACHI LABORATORIES LIMITED

Digitally signed by
T RAJASEKHAR
RAJASEKHAR Date: 2020.11.13
16:33:17 +05'30'

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 13.11.2020

niranjan & narayan

Chartered Accountants

FRN : 005899S

GSTIN : 36AACFN0604K1ZJ

first floor, h.no: 7-1-28/1/A/21

shyamkaran road, ameerpeta

hyderabad - 500 016

tel : 29806074, cell : 9490189487

email : caniranjan@yahoo.com

www.nncas.com

INDEPENDENT AUDITORS' REVIEW REPORT

To
The Board of Directors,
Sigachi Laboratories Limited,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited ("the company") for the quarter ended 30th September, 2020 and year to date results for the period from 1st April, 2020 to 30th September, 2020, ("the statement") being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind As 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these interim financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the interim financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting principles generally accepted, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 13.11.2020

Place : Hyderabad



For Niranjana & Narayan
Chartered Accountants

FRN: 005899S

M. Niranjana

M. Niranjana

Partner - Memb. No. 029552

UDIN: 20029552AAAALS2034